Dario Signs Two Employers For Cardiometabolic Suite With Integrated GLP-1 Solution, Beginning In Q2 Of 2024
Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health
NEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.
The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.
Dario combines intelligent technologies with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep members engaged over time for optimal results. Employees enrolled in Dario's cardiometabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.
"The trend towards integrated solutions continues to grow as employers look to reduce point solutions in favor of a single integrated solution that has a better member experience and has a lower cost of ownership when compared to managing multiple point solutions. Our new accounts are excited about Dario's proven ability to effectively engage people across multiple related conditions, and we look forward to delivering the market-leading results our clients deserve," said Rick Anderson, President of Dario.